Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric derisomaltose in non-anemic iron-deficient patients with colorectal cancer undergoing curative surgery
2024-518517-26-00Phase 2Authorised
- Sponsor
- Region Zealand
- Start
- Oct 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Region Zealand. Primary endpoints: Change in cellular respiration, Preoperative change in neutrophil-to-lymphocyte ratio and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2024-518517-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518517-26-00.